Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 4/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL25253575 | 0.94 | PDE10A (0.33) | PDE10ATRPV1KIF11PIK3CADHFR | |
| Formic Acid SCHEMBL30467685 | 0.94 | PDE10A (0.33) | PDE10ATRPV1KIF11PIK3CADHFR | |
| SCHEMBL26771225 | 0.93 | PDE10A (0.34) | PDE10ATRPV1KIF11 | |
| SCHEMBL25253573 | 0.84 | PDE10A (0.31) | PDE10ATRPV1 | |
| SCHEMBL24252496 | 0.82 | PDE10A (0.44) | PDE10ADHFRLRRK2 | |
| Formic Acid SCHEMBL30467562 | 0.78 | PDE10A (0.41) | PDE10ADHFRLRRK2 | |
| Formic Acid SCHEMBL25244082 | 0.78 | PDE10A (0.41) | PDE10ADHFRLRRK2 | |
| SCHEMBL26771199 | 0.76 | PDE10A (0.43) | PDE10ADHFRLRRK2 | |
| SCHEMBL30467718 | 0.75 | RXRA (0.33) | PDE10ADHFRLRRK2 | |
| SCHEMBL24252297 | 0.75 | RXRA (0.33) | PDE10ADHFRLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | PDE10A 1950/4885TRPV1 3867/4885KIF11 4721/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | PDE10A 1950/4885TRPV1 3867/4885KIF11 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.